InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by LINDAHL RICHARD S, Chief Financial Officer. Officer active across 1 companies, notably Emergent BioSolutions Inc.. Cumulatively, 7 disclosures have been published. Total volume traded: €196k. The latest transaction was disclosed on 1 March 2022 — Attribution. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations7 total
031,417 shares0
Common Stock
SEC:0001367644-22-000042:0·
€19,234516 shares@ €37.27560.0047% mcap5.9% of flow
Common Stock
SEC:0001367644-22-000032:0·
01,836 shares0
Common Stock
SEC:0001367644-22-000020:0·
€98,2203,000 shares@ €32.740.024% mcap64.6% of flow
Common Stock
SEC:0001367644-21-000144·
Ideal exit: 12 Aug 2022 (T+270)
€98,2203,000 shares@ €32.740.024% mcap30.4% of flow
Common Stock
SEC:0001367644-21-000144:0·
Ideal exit: 12 Aug 2022 (T+270)
€53,8151,054 shares@ €51.05830.013% mcap35.4% of flow
Common Stock
SEC:0001367644-21-000079·
€53,8151,054 shares@ €51.05830.013% mcap16.6% of flow
Common Stock
SEC:0001367644-21-000079:0·
7 of 7 declarations
About LINDAHL RICHARD S
Richard S. Lindahl is the Chief Financial Officer and EVP of Emergent BioSolutions Inc. In this role, he is responsible for the financial management of the company, including financial planning and risk management. With significant experience in the biopharmaceutical sector, he contributes to the financial strategy and growth of the company. His expertise is essential for ensuring profitability and sustainability.
